Why carry out this study?

Psoriasis (PsO) is frequently accompanied by comorbidities that confound diagnosis and complicate management in the real-world setting

Secukinumab, a fully human monoclonal interleukin-17A antibody, has been demonstrated to be effective and safe for the treatment of patients with PsO in several clinical trials

However, these studies only offer limited data on the use of secukinumab in the treatment of patients with chronic illnesses that may render patients immunocompromised or in special populations; therefore, there is an unmet need to evaluate the efficacy and safety of secukinumab treatment in these challenging-to-treat special populations

What was learned from the study?

Although there is a paucity of data on the use of secukinumab in challenging treatment scenarios, secukinumab has demonstrated effectiveness in some challenging populations and has a consistent safety profile for more than 5 years across its approved indications, indicating that secukinumab may be a viable option among patients with chronic illness and in special populations

This review provides insight into the use of secukinumab in patients with PsO who have confounding comorbidities and highlights the current gaps in knowledge associated with treatment of these special populations